Tags

Type your tag names separated by a space and hit enter

Integration of Tumor-Treating Fields into the Multidisciplinary Management of Patients with Solid Malignancies.

Abstract

Tumor-treating fields (TTFields) are a noninvasive antimitotic cancer treatment consisting of low-intensity alternating electric fields delivered to the tumor or tumor bed via externally applied transducer arrays. In multiple in vitro and in vivo cancer cell lines, TTFields therapy inhibits cell proliferation, disrupts cell division, interferes with cell migration and invasion, and reduces DNA repair. Human trials in patients with primary glioblastoma showed an improvement in overall survival, and trials in patients with unresectable malignant pleural mesothelioma showed favorable outcomes compared with historical control. This led to U.S. Food and Drug Administration approval in both clinical situations, paving the way for development of trials investigating TTFields in other malignancies. Although these trials are ongoing, the existing evidence suggests that TTFields have activity outside of neuro-oncology, and further study into the mechanism of action and clinical activity is required. In addition, because TTFields are a previously unrecognized antimitotic therapy with a unique mode of delivery, the oncological community must address obstacles to widespread patient and provider acceptance. TTFields will likely join surgery, systemic therapy, and radiation therapy as a component of multimodality management of patients with solid malignancies.

IMPLICATIONS FOR PRACTICE:

Tumor-treating fields (TTFields) exhibit a broad range of antitumor activities. Clinically, they improve overall survival for patients with newly diagnosed glioblastoma. The emergence of TTFields has changed the treatment regimen for glioblastoma. Clinicians need to understand the practical issues surrounding its use in the multidisciplinary management of patients with glioblastoma. With ongoing clinical trials, TTFields likely will become another treatment modality for solid malignancies.

Authors+Show Affiliations

Department of Radiation Oncology, West Cancer Center and Research Institute, Memphis, Tennessee, USA.Department of Hematology/Oncology, West Cancer Center and Research Institute, Memphis, Tennessee, USA.Department of Radiation Oncology, West Cancer Center and Research Institute, Memphis, Tennessee, USA mballo@westclinic.com.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

31444292

Citation

Wang, Yuefeng, et al. "Integration of Tumor-Treating Fields Into the Multidisciplinary Management of Patients With Solid Malignancies." The Oncologist, 2019.
Wang Y, Pandey M, Ballo MT. Integration of Tumor-Treating Fields into the Multidisciplinary Management of Patients with Solid Malignancies. Oncologist. 2019.
Wang, Y., Pandey, M., & Ballo, M. T. (2019). Integration of Tumor-Treating Fields into the Multidisciplinary Management of Patients with Solid Malignancies. The Oncologist, doi:10.1634/theoncologist.2017-0603.
Wang Y, Pandey M, Ballo MT. Integration of Tumor-Treating Fields Into the Multidisciplinary Management of Patients With Solid Malignancies. Oncologist. 2019 Aug 23; PubMed PMID: 31444292.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Integration of Tumor-Treating Fields into the Multidisciplinary Management of Patients with Solid Malignancies. AU - Wang,Yuefeng, AU - Pandey,Manjari, AU - Ballo,Matthew T, Y1 - 2019/08/23/ PY - 2017/11/15/received PY - 2019/05/28/revised PY - 2019/06/10/accepted PY - 2019/8/25/entrez KW - Alternating electric fields KW - Glioblastoma KW - Optune KW - Solid malignancy KW - Tumor‐treating fields JF - The oncologist JO - Oncologist N2 - Tumor-treating fields (TTFields) are a noninvasive antimitotic cancer treatment consisting of low-intensity alternating electric fields delivered to the tumor or tumor bed via externally applied transducer arrays. In multiple in vitro and in vivo cancer cell lines, TTFields therapy inhibits cell proliferation, disrupts cell division, interferes with cell migration and invasion, and reduces DNA repair. Human trials in patients with primary glioblastoma showed an improvement in overall survival, and trials in patients with unresectable malignant pleural mesothelioma showed favorable outcomes compared with historical control. This led to U.S. Food and Drug Administration approval in both clinical situations, paving the way for development of trials investigating TTFields in other malignancies. Although these trials are ongoing, the existing evidence suggests that TTFields have activity outside of neuro-oncology, and further study into the mechanism of action and clinical activity is required. In addition, because TTFields are a previously unrecognized antimitotic therapy with a unique mode of delivery, the oncological community must address obstacles to widespread patient and provider acceptance. TTFields will likely join surgery, systemic therapy, and radiation therapy as a component of multimodality management of patients with solid malignancies. IMPLICATIONS FOR PRACTICE: Tumor-treating fields (TTFields) exhibit a broad range of antitumor activities. Clinically, they improve overall survival for patients with newly diagnosed glioblastoma. The emergence of TTFields has changed the treatment regimen for glioblastoma. Clinicians need to understand the practical issues surrounding its use in the multidisciplinary management of patients with glioblastoma. With ongoing clinical trials, TTFields likely will become another treatment modality for solid malignancies. SN - 1549-490X UR - https://www.unboundmedicine.com/medline/citation/31444292/Integration_of_Tumor-Treating_Fields_into_the_Multidisciplinary_Management_of_Patients_with_Solid_Malignancies L2 - http://theoncologist.alphamedpress.org/cgi/pmidlookup?view=long&pmid=31444292 DB - PRIME DP - Unbound Medicine ER -